You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 16, 2026

Claims for Patent: 11,124,578


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,124,578
Title:Method of treating transplant rejection with silent Fc variants of anti-CD40 antibodies
Abstract:The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
Inventor(s):Heusser Christoph, Rush James, Vincent Karen
Assignee:NOVARTIS AG
Application Number:US16399250
Patent Claims:

Details for Patent 11,124,578

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 August 24, 1998 11,124,578 2039-04-30
Immunex Corporation ENBREL etanercept For Injection 103795 November 02, 1998 11,124,578 2039-04-30
Immunex Corporation ENBREL etanercept For Injection 103795 May 27, 1999 11,124,578 2039-04-30
Immunex Corporation ENBREL etanercept Injection 103795 September 27, 2004 11,124,578 2039-04-30
Immunex Corporation ENBREL etanercept Injection 103795 February 01, 2007 11,124,578 2039-04-30
Immunex Corporation ENBREL MINI etanercept Injection 103795 September 14, 2017 11,124,578 2039-04-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 11,124,578

Country Patent Number Estimated Expiration
South Africa 201302532 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2012065950 ⤷  Get Started Free
Uruguay 39292 ⤷  Get Started Free
Uruguay 33728 ⤷  Get Started Free
United States of America 9828433 ⤷  Get Started Free
United States of America 9688768 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.